Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1960 1
1962 2
1964 1
1968 1
1969 2
1970 2
1974 1
1990 1
2002 1
2004 1
2005 5
2007 2
2008 2
2009 1
2011 2
2013 2
2014 4
2015 5
2016 10
2017 6
2018 6
2019 11
2020 16
2021 15
2022 14
2023 11
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

128 results

Results by year

Filters applied: . Clear all
Page 1
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme-Beaty E, Rosenstock B, Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK; INBUILD Trial Investigators. Flaherty KR, et al. N Engl J Med. 2019 Oct 31;381(18):1718-1727. doi: 10.1056/NEJMoa1908681. Epub 2019 Sep 29. N Engl J Med. 2019. PMID: 31566307 Clinical Trial.
Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M; INBUILD trial investigators. Wells AU, et al. Lancet Respir Med. 2020 May;8(5):453-460. doi: 10.1016/S2213-2600(20)30036-9. Epub 2020 Mar 5. Lancet Respir Med. 2020. PMID: 32145830 Clinical Trial.
Update in Pulmonary Fibrosis 2018.
Sgalla G, Kulkarni T, Antin-Ozerkis D, Thannickal VJ, Richeldi L. Sgalla G, et al. Among authors: kulkarni t. Am J Respir Crit Care Med. 2019 Aug 1;200(3):292-300. doi: 10.1164/rccm.201903-0542UP. Am J Respir Crit Care Med. 2019. PMID: 31022351 Review. No abstract available.
Probiotic sepsis in preterm neonates-a systematic review.
Kulkarni T, Majarikar S, Deshmukh M, Ananthan A, Balasubramanian H, Keil A, Patole S. Kulkarni T, et al. Eur J Pediatr. 2022 Jun;181(6):2249-2262. doi: 10.1007/s00431-022-04452-5. Epub 2022 Mar 29. Eur J Pediatr. 2022. PMID: 35348825 Review.
The Immunopathobiology of SARS-CoV-2 Infection.
Patel M, Shahjin F, Cohen JD, Hasan M, Machhi J, Chugh H, Singh S, Das S, Kulkarni TA, Herskovitz J, Meigs DD, Chandra R, Hettie KS, Mosley RL, Kevadiya BD, Gendelman HE. Patel M, et al. Among authors: kulkarni ta. FEMS Microbiol Rev. 2021 Nov 23;45(6):fuab035. doi: 10.1093/femsre/fuab035. FEMS Microbiol Rev. 2021. PMID: 34160586 Free PMC article.
Matrix Remodeling in Pulmonary Fibrosis and Emphysema.
Kulkarni T, O'Reilly P, Antony VB, Gaggar A, Thannickal VJ. Kulkarni T, et al. Am J Respir Cell Mol Biol. 2016 Jun;54(6):751-60. doi: 10.1165/rcmb.2015-0166PS. Am J Respir Cell Mol Biol. 2016. PMID: 26741177 Free PMC article. Review.
Levetiracetam-induced systemic lupus erythematosus.
Jadhav P, Kulkarni T, Jadhav J, Desai S, Baviskar R. Jadhav P, et al. Among authors: kulkarni t. J R Coll Physicians Edinb. 2021 Mar;51(1):58-60. doi: 10.4997/JRCPE.2021.114. J R Coll Physicians Edinb. 2021. PMID: 33877137
Non-Viral Vectors for Delivery of Nucleic Acid Therapies for Cancer.
Kanvinde S, Kulkarni T, Deodhar S, Bhattacharya D, Dasgupta A. Kanvinde S, et al. Among authors: kulkarni t. BioTech (Basel). 2022 Mar 7;11(1):6. doi: 10.3390/biotech11010006. BioTech (Basel). 2022. PMID: 35822814 Free PMC article. Review.
128 results